Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Inwards

Showing results (81-90 of 179) with videos related to

Pageof 18
Sort By:
Haematologica|October 14, 2011
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaLuis F Porrata, Kay Ristow, Joseph P Colgan, et al.
Leukemia & Lymphoma|April 22, 2014
Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivorsSarah Rausch Osian, Alexis D Leal, Cristine Allmer, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2016
Immunologic Autograft Engineering and Survival in Non-Hodgkin LymphomaLuis F Porrata, Edwin A Burgstaler, Jeffrey L Winters, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Cancer|October 20, 2011
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)Tait D Shanafelt, Neil E Kay, Kari G Rabe, et al.
Scientific Reports|December 1, 2023
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patientsMary J Kasten, Brian D Lahr, Anusha Parisapogu, et al.
Blood Cancer Journal|September 26, 2021
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E studySanjal H Desai, Betsy LaPlant, William R Macon, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
Pageof 18

Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
Haematologica|October 14, 2011
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaLuis F Porrata, Kay Ristow, Joseph P Colgan, et al.
Leukemia & Lymphoma|April 22, 2014
Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivorsSarah Rausch Osian, Alexis D Leal, Cristine Allmer, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2016
Immunologic Autograft Engineering and Survival in Non-Hodgkin LymphomaLuis F Porrata, Edwin A Burgstaler, Jeffrey L Winters, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Cancer|October 20, 2011
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)Tait D Shanafelt, Neil E Kay, Kari G Rabe, et al.
Scientific Reports|December 1, 2023
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patientsMary J Kasten, Brian D Lahr, Anusha Parisapogu, et al.
Blood Cancer Journal|September 26, 2021
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E studySanjal H Desai, Betsy LaPlant, William R Macon, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
Pageof 18